Evofem Biosciences, Inc. CEO Saundra Pelletier Discusses Why $EVFM is a Company to Watch
Detroit, MI --News Direct-- Benzinga
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a biopharmaceutical company developing & commercializing products to address needs in women's sexual & reproductive health. The Company's 1st FDA-approved product, Phexxi® (lactic acid, citric acid & potassium bitartrate), is a hormone-free prescription contraceptive vaginal gel. The Company may report top-line data in fall 2022 from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for 2 potential new indications – prevention of chlamydia & of gonorrhea in women. Visit phexxi.com & evofem.com.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View original content to download multimedia: https://newsdirect.com/news/evofem-biosciences-inc-ceo-saundra-pelletier-discusses-why-evfm-is-a-company-to-watch-625266353
This news release was distributed by News Direct Corp. (“News Direct”). News Direct is an industry-leading content and news distribution platform. This news release and all materials included within this news release, including, without limitation, all images, trademarks and logos, are protected by copyrights, trademarks, service marks, patents or other proprietary rights and laws. If you copy, broadcast, download, store (in any medium), transmit, show or play any multimedia content from this release in public, you must properly attribute said content to the company or organization from which the news release originated unless otherwise sourced. News Direct makes no warranties with respect to the accuracy or completeness of the information contained in this news release. News Direct hereby disclaims all warranties, whether express, implied, statutory or otherwise, in connection with this news release and the content within this news release.
